Benzinga | May 6, 2021 06:57AM EDT

Annovis Bio Receives US Patent For Method Of Treating Frontotemporal Dementia And Chronic Traumatic Encephalopathy

Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the U.S. Patent and Trademark Office (USPTO) granted the Company's patent (US 16/504,813) for a method of treating tauopathies, such as frontotemporal dementia and chronic traumatic encephalopathy by administering ANVS401.